A Phase I Trial of Enzastaurin (LY317615) in Patients With Recurrent Gliomas.

Trial Profile

A Phase I Trial of Enzastaurin (LY317615) in Patients With Recurrent Gliomas.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs Enzastaurin (Primary)
  • Indications Anaplastic astrocytoma; Astrocytoma; CNS cancer; Glioblastoma; Glioma; Oligodendroglioma
  • Focus Adverse reactions
  • Most Recent Events

    • 29 Sep 2011 Planned end date changed from 1 Jan 2006 to 1 Apr 2008 as reported by ClinicalTrials.gov.
    • 29 Sep 2011 Planned end date changed from 1 Jan 2006 to 1 Apr 2008 as reported by ClinicalTrials.gov.
    • 19 Oct 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top